1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse 
drug reactions in hospitalized patients: A meta‑analysis of 
prospective studies. JAMA 1998;279:1200‑5.
2. Pirmohamed M, James S, Meakin S, Green C, Scott AK, 
Walley TJ, et al. Adverse drug reactions as cause of admission 
to hospital: Prospective analysis of 18 820 patients. BMJ 
2004;329:15‑9.
3. Wu Z, Van de Werf F, Stassen T, Mattsson C, Pohl G, Collen D. 
Pharmacokinetics and coronary thrombolytic properties 
of two human tissue‑type plasminogen activator variants 
lacking the finger‑like, growth factor‑like, and first kringle 
domains (amino acids 6‑173) in a canine model. J Cardiovasc 
Pharmacol 1990;16:197‑203.
4. Smalling RW, Bode C, Kalbfleisch J, Sen S, Limbourg P, 
Forycki F, et al. More rapid, complete, and stable coronary 
thrombolysis with bolus administration of reteplase compared 
with alteplase infusion in acute myocardial infarction. RAPID 
investigators. Circulation 1995;91:2725‑32.
5. BodeC, SmallingRW, BergG, BurnettC, LorchG, KalbfleischJM, 
et al. Randomized comparison of coronary thrombolysis 
achieved with double‑bolus reteplase (recombinant 
plasminogen activator) and front‑loaded, accelerated 
alteplase (recombinant tissue plasminogen activator) in 
patients with acute myocardial infarction. The RAPID II 
investigators. Circulation 1994;94:891‑8.
6. American College of Emergency Physicians; Society for 
Cardiovascular Angiography and Interventions, O’Gara PT, 
Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, et al. 2013 
ACCF/AHA guideline for the management of ST‑elevation 
myocardial infarction: A report of the American College 
of Cardiology Foundation/American Heart Association 
Task Force on Practice Guidelines. J Am Coll Cardiol 
2013;61:e78‑140.
7. BodeC, SmallingRW, BergG, BurnettC, LorchG, KalbfleischJM, 
et al. Randomized comparison of coronary thrombolysis 
achieved with double‑bolus reteplase (recombinant 
plasminogen activator) and front‑loaded, accelerated 
alteplase (recombinant tissue plasminogen activator) in 
patients with acute myocardial infarction. The RAPID II 
investigators. Circulation 1996;94:891‑8.
8. Topol EJ, Ohman EM, Armstrong PW, Wilcox R, Skene AM, 
Aylward P, et al. Survival outcomes 1 year after reperfusion 
therapy with either alteplase or reteplase for acute myocardial 
infarction: Results from the Global Utilization of Streptokinase 
and t‑PA for Occluded Coronary Arteries (GUSTO) III Trial. 
Circulation 2000;102:1761‑5.
9. A comparison of reteplase with alteplase for acute myocardial 
infarction. The Global Use of Strategies to Open Occluded 
Coronary Arteries (GUSTO III) Investigators. N Engl J Med 
1997;337:1118‑23.
10. Hampton JR, Schroder R, Wilcox RG, Skene AM, 
Meyer‑Sabellek W, Heikkila J, et al. Randomized double‑blind 
comparison of reteplase double‑bolus administration with 
streptokinase in acute myocardial infarction (INJECT): Trial 
to investigate equivalence. Lancet 1995;346:329‑36.
11. Antman EM, Anbe DT, Armstrong PW, Bates ER, 
Green LA, Hand M, et al. ACC/AHA guidelines for the 
management of patients with ST‑elevation myocardial 
infarction – Executive summary. A report of the American 
College of Cardiology/American Heart Association Task 
Force on Practice Guidelines (writing committee to revise the 
1999 guidelines for the management of patients with acute 
myocardial infarction). J Am Coll Cardiol 2004;44:671‑719.
12. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, 
et al. A method for estimating the probability of adverse drug 
reactions. Clin Pharmacol Ther 1981;30:239‑45.
13. ShahK, ApsangikarP, AlluJ, Chaudhry S. Clinical retrospective 
and prospective evaluation of efficacy and safety of reteplase 
in STEMI patients. Indian Med Gaz 2012;146:479-87.
14. Singh RK, Trailokya A, Naik MM. Post‑reteplase evaluation 
of clinical safety and efficacy in Indian patients (Precise‑In 
Study). J Assoc Physicians India 2015;63:30‑5.
15. Domecq C, Naranjo CA, Ruiz I, Busto U. Sex‑related variations 
in the frequency and characteristics of adverse drug reactions. 
Int J Clin Pharmacol Ther Toxicol 1980;18:362‑6.
16. Martin RM, Biswas PN, Freemantle SN, Pearce GL, Mann RD. 
Age and sex distribution of suspected adverse drug reactions to 
newly marketed drugs in general practice in England: Analysis 
of 48 cohort studies. Br J Clin Pharmacol 1998;46:505‑11.
17. Retavase product insert monograph.  Germany: Boehringer 
Mannheim GmbH, Centocor, Inc.; 1999.
18. Thong BY, Tan TC. Epidemiology and risk factors for drug 
allergy. Br J Clin Pharmacol 2011;71:684‑700.
19. O’Mahony MS, Woodhouse KW. Age, environmental factors 
and drug metabolism. Pharmacol Ther 1994;61:279‑87.
20. Routledge PA, O’Mahony MS, Woodhouse KW. Adverse drug 
reactions in elderly patients. Br J Clin Pharmacol 2004;57:121‑6.
21. Zaman Huri H, Fun Wee H. Drug related problems in 
type 2 diabetes patients with hypertension: A cross‑sectional 
retrospective study. BMC Endocr Disord 2013;13:2.